Evidence map›Paper›PMID 39807605›Full record

ArticleAdvances in clinical and experimental medicine : official organ Wroclaw Medical University2025

Experience with sodium glucose cotransporter-2 inhibitors in adult patients with Fontan circulation.

Paweł Skorek, Magdalena M Frączek-Jucha, Agnieszka Sarnecka, Maciej Skubera, Natasza Libiszewska, Lidia Tomkiewicz-Pająk

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Advances in clinical and experimental medicine : official organ Wroclaw Medical University, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07482943 (The Effect of Dapagliflozin on Exercise and Cardiac Functional Status of Patients After Fontan Procedure), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07482943 phase4recruitingstarted 2026, after this paper: background citation

The Effect of Dapagliflozin on Exercise and Cardiac Functional Status of Patients After Fontan Procedure

Ran2026Enrolled30Registered outcomes13Posted comparisons0ConditionsCardiovascular Diseases, Dapagliflozin, Fontan, Heart FailureArmsDapagliflozin (5-10 mg daily) - SGLT2 Inhibitor Therapy
PMID 32098807PMID 35379503PMID 34936056PMID 34900549PMID 35948644PMID 36530388PMID 37615988PMID 37919530PMID 11889012PMID 17543747PMID 34447992PMID 33736819other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Paweł SkorekDoctoral School of Medical and Health Sciences, Jagiellonian University Medical College, Cracow, Poland.
Magdalena M Frączek-JuchaInstitute of Cardiology, Jagiellonian University Medical College, Cracow, Poland.
Agnieszka SarneckaInstitute of Cardiology, Jagiellonian University Medical College, Cracow, Poland.
Maciej SkuberaInstitute of Cardiology, Jagiellonian University Medical College, Cracow, Poland.
Natasza LibiszewskaInstitute of Cardiology, Jagiellonian University Medical College, Cracow, Poland.
Lidia Tomkiewicz-PająkInstitute of Cardiology, Jagiellonian University Medical College, Cracow, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe still know little about the effective pharmacological treatment of heart failure (HF) associated with the Fontan circulation. One of the new options may be sodium glucose cotransporter-2 inhibitors (SGLT2i), which have been proven effective in classic forms of left ventricular HF.

objectivesTo evaluate the effect and safety of SGLT2i inclusion in adults with Fontan circulation. To this end, we conducted observation and complex diagnostics of adult Fontan patients in whom we started treatment with flozins. MATERIAL AND

methodsThe study population consisted of 17 adult Fontan patients with average age 30.5 (9.7) years, 59% in II New York Heart Association (NYHA) class, among whom 53% received dapagliflozin and rest empagliflozin.

resultsThe average observation time was 11.0 (3.7) months. None of the patients have reported side effects or complications related to treatment. We observed a significant increase (20.1 mL/kg/min vs 24.2 mL/kg/min, p = 0.008) in the median of maximum oxygen uptake (VO2 max) among participants (9) who completed at least 2 reliable cardiopulmonary exercise tests. We did not notice any significant differences in N-terminal prohormone of brain natriuretic peptide concentration (641.35 (923.7) vs 741.47 (1,139.02), p = 0.12) after the inclusion. Interestingly, we observed a significant increase in erythrocytes (+6%, p = 0.003), hemoglobin (+7%, p = 0.03) and hematocrit (+7%, p = 0.02).

conclusionsTo the best of our knowledge, this is the first study to demonstrate that the implementation of SGLT2i may have a positive effect on exercise capacity among adults with Fontan circulation. Our experience confirms the high safety of using these drugs in Fontan adults.

Indexed as

Benzhydryl CompoundsFontan ProcedureHeart FailureSodium-Glucose Transporter 2 InhibitorsAdultExercise TestFemaleGlucosidesHumansMaleTreatment OutcomeYoung AdultBenzhydryl CompoundsdapagliflozinempagliflozinGlucosidesSodium-Glucose Transporter 2 Inhibitorscongenital heart diseaseflozinsFontan circulationheart failure

Identifiers

PMID39807605

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.